CD19 and prostate neoplasm: We found that the tumors having ‘low’ NKX3.1 expression had relatively increased expression of PTPRC (coding for CD45), CD3G, CD68 and CD19, which mark leukocytes, T cells, macrophages and B cells, respectively, but not CEACAM8 (CD66b) a marker of granulocyte cells, which was generally expressed at very low levels or not detected in the human prostate tumors (Fig. 1E).